Expanded low allele frequency RAS and BRAF V600E testing in metastatic colorectal cancer as predictive biomarkers for cetuximab in the randomized CO.17 trial

BACKGROUND: Expanded RAS/BRAF mutations have not been assessed as predictive for single-agent cetuximab in metastatic colorectal cancer (mCRC) and low mutant allele frequency (MAF) mutations are of unclear significance. We aimed to establish cetuximab efficacy in optimally selected patients using hi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Loree, Jonathan M., Dowers, Anthony, Tu, Dongsheng, Jonker, Derek J., Edelstein, Daniel L., Quinn, Hannah, Holtrup, Frank, Price, Timothy, Zalcberg, John R., Moore, Malcolm J., Karapetis, Christos S., O’Callaghan, Chris J., Waring, Paul, Kennecke, Hagen F., Hamilton, Stanley R., Kopetz, Scott
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7785657/
https://ncbi.nlm.nih.gov/pubmed/33087330
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-2710
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars